Lorena Monge Galindo

Lorena Monge Galindo

Auto-generated profile, based on publicly available information

Lorena Monge Galindo

HUMS. Hospital Universitario Miguel Servet, 50009 Zaragoza, Espana

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet Neurology
Verified
Journal Article
Open access
TAThaís Armangue
Thaís Armangue
MSMarianna Spatola
Marianna Spatola
AVAlexandru Vlagea
Alexandru Vlagea
SMSimone Mattozzi
Simone Mattozzi
MCMarc Cárceles-Cordon
Marc Cárceles-Cordon
AZAna Zabalza
Ana Zabalza
Herpes simplex encephalitis can trigger autoimmune encephalitis that leads to neurological worsening. We aimed to assess the frequency, symptoms, risk factors, and outcomes of this complication. We did a prospective observational study and retrospective analysis. In the prospective observational part of this study, we included patients with herpes simplex encephalitis diagnosed by neurologists, paediatricians, or infectious disease specialists in 19 secondary and tertiary Spanish centres (Cohort A). Outpatient follow-up was at 2, 6, and 12 months from onset of herpes simplex encephalitis. We studied another group of patients retrospectively, when they developed autoimmune encephalitis after herpes simplex encephalitis (Cohort B). We compared demographics and clinical features of patients who developed autoimmune encephalitis with those who did not, and in patients who developed autoimmune encephalitis we compared these features by age group (patients ≤4 years compared with patients >4 years). We also used multivariable binary logistic regression models to assess risk factors for autoimmune encephalitis after herpes simplex encephalitis. Between Jan 1, 2014, and Oct 31, 2017, 54 patients with herpes simplex encephalitis were recruited to Cohort A, and 51 were included in the analysis (median age 50 years [IQR 5-68]). At onset of herpes simplex encephalitis, none of the 51 patients had antibodies to neuronal antigens; during follow-up, 14 (27%) patients developed autoimmune encephalitis and all 14 (100%) had neuronal antibodies (nine [64%] had NMDA receptor [NMDAR] antibodies and five [36%] had other antibodies) at or before onset of symptoms. The other 37 patients did not develop autoimmune encephalitis, although 11 (30%) developed antibodies (n=3 to NMDAR, n=8 to unknown antigens; p<0·001). Antibody detection within 3 weeks of herpes simplex encephalitis was a risk factor for autoimmune encephalitis (odds ratio [OR] 11·5, 95% CI 2·7-48·8; p<0·001). Between Oct 7, 2011, and Oct 31, 2017, there were 48 patients in Cohort B with new-onset or worsening neurological symptoms not caused by herpes simplex virus reactivation (median age 8·8 years [IQR 1·1-44·2]; n=27 male); 44 (92%) patients had antibody-confirmed autoimmune encephalitis (34 had NMDAR antibodies and ten had other antibodies). In both cohorts (n=58 patients with antibody-confirmed autoimmune encephalitis), patients older than 4 years frequently presented with psychosis (18 [58%] of 31; younger children not assessable). Compared with patients older than 4 years, patients aged 4 years or younger (n=27) were more likely to have shorter intervals between onset of herpes simplex encephalitis and onset of autoimmune encephalitis (median 26 days [IQR 24-32] vs 43 days [25-54]; p=0·0073), choreoathetosis (27 [100%] of 27 vs 0 of 31; p<0·001), decreased level of consciousness (26 [96%] of 27 vs seven [23%] of 31; p<0·001), NMDAR antibodies (24 [89%] of 27 vs 19 [61%] of 31; p=0·033), and worse outcome at 1 year (median modified Rankin Scale 4 [IQR 4-4] vs 2 [2-3]; p<0·0010; seizures 12 [63%] of 19 vs three [13%] of 23; p=0·001). The results of our prospective study show that autoimmune encephalitis occurred in 27% of patients with herpes simplex encephalitis. It was associated with development of neuronal antibodies and usually presented within 2 months after treatment of herpes simplex encephalitis; the symptoms were age-dependent, and the neurological outcome was worse in young children. Prompt diagnosis is important because patients, primarily those older than 4 years, can respond to immunotherapy. Mutua Madrileña Foundation, Fondation de l'Université de Lausanne et Centre Hospitalier Universitaire Vaudois, Instituto Carlos III, CIBERER, National Institutes of Health, Generalitat de Catalunya, Fundació CELLEX.

1 March 2020 in The Lancet Neurology
Verified
Journal Article
Closed access
TAThaís Armangue
Thaís Armangue
GOGemma Olivé-Cirera
Gemma Olivé-Cirera
EMEugenia Martínez-Hernandez
Eugenia Martínez-Hernandez
MSMaria Sepulveda
Maria Sepulveda
RRRaquel Ruiz-Garcia
Raquel Ruiz-Garcia
CVCristina Villar-Vera
Cristina Villar-Vera

12 April 2016 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
AMAnna Marcé-Grau
Anna Marcé-Grau
JDJames Dalton
James Dalton
JLJavier López-Pisón
Javier López-Pisón
MJMARIA CONCEPCION GARCIA JIMENEZ
MARIA CONCEPCION GARCIA JIMENEZ
LMLorena Monge-Galindo
Lorena Monge-Galindo
AMAlfons Macaya
Alfons Macaya
De novo heterozygous mutations in the GNAO1 gene, encoding the Gα o subunit of G-proteins, are the cause of a severe neurodevelopmental disorder, featuring early infantile seizures, profound cognitive dysfunction and, occasionally, movement disorder (early infantile epileptic encephalopathy-17). We report a further case of this association in a 20 month-old Spanish girl with neonatal-onset refractory seizures, progressive microcephaly, oral-lingual dyskinesia and nearly absent psychomotor development. We performed whole-exome sequencing, a computational structural analysis of the novel gene variant identified and reviewed the previously reported cases. Trio whole-exome-sequencing uncovered a de novo p.Leu199Pro GNAO1 mutation. Computational structural analysis indicates this novel variant adversely affects the stability of the G-protein heterotrimeric complex as a whole. Of note, our patient showed a sustained seizure reduction while on a ketogenic diet. With this observation, a total of twelve patients with GNAO1 encephalopathy have been reported. Oral-lingual dyskinesia and responsiveness of seizures to ketogenic diet are novel features. The distorted sex ratio (12/12 females) of the condition remains unexplained; a differential gender effect of the disruption of G-protein- mediated signal transduction on the developing brain can be hypothesized.

1 January 2014 in Neurología
Verified
Journal Article
Closed access
LGL. Monge Galindo
L. Monge Galindo
JLJ. López-Pisón
J. López-Pisón
PVP. Samper Villagrasa
P. Samper Villagrasa
JSJ.L. Peña Segura
J.L. Peña Segura

1 November 2009 in Anales de Pediatría
Verified
Journal Article
Closed access
LGL. Monge Galindo
L. Monge Galindo
RDR. Pérez Delgado
R. Pérez Delgado
JLJ. López-Pisón
J. López-Pisón
AOA. Olloqui-Escalona
A. Olloqui-Escalona
JÍJ.P. García Íñiguez
J.P. García Íñiguez
JPJ.L. Peña-Segura
J.L. Peña-Segura

1 September 2014 in Neurología
Verified
Journal Article
Closed access
JLJ. López-Pisón
J. López-Pisón
MGM.C. García-Jiménez
M.C. García-Jiménez
LML. Monge-Galindo
L. Monge-Galindo
MLM. Lafuente-Hidalgo
M. Lafuente-Hidalgo
RPR. Pérez-Delgado
R. Pérez-Delgado
JPJ.L. Peña-Segura
J.L. Peña-Segura